|
Dr. Champlin is Professor of Medicine, and Chairman of the Department of Blood and Marrow Transplantation at the University of Texas M. D. Anderson Cancer Center. He graduated from the University of Chicago's Pritzker School of Medicine, before completing post-graduate training at the UCLA School of Medicine, Los Angeles. Professor Champlin has been an Assistant and Associate Professor of Medicine and directed the Transplantation Biology Program at the UCLA Center for the Health Sciences before assuming his current post.
Professor Champlin chairs the Working Committee on Alternative Donors and Cell Sources of the International Bone Marrow Transplant Registry. He was the founding president of the American Society of Blood and Marrow Transplantation and past president of the Council for Donor, Transplant and Collection Centers for the National Marrow Donor Program. He is vice president of the Foundation for Accreditation of Hematocellular Therapy and a member of the Biologic Response Modifiers Advisory Board for the FDA and the Hematology Board, American Board of Internal Medicine. Dr. Champlin is a member of several scientific societies and serves on the Editorial Boards of Blood, Bone Marrow Transplantation and Journal of Hematotherapy. His current research interests include the investigation of non-myeloablative conditioning prior to allogeneic transplantation and the use of allogeneic and autologous hematopoietic transplantation for hematologic malignancies and selected solid tumors. | 